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In recent years, ample attention has been directed towards the mechanisms that play a major role in the
process of vascular graft failure, especially graft thrombosis and intimal narrowing have been high-
lighted. In this article, a survey is conducted into the key mechanisms of the biological processes of
intimal hyperplasia and ultimate graft failure. The sequence of biochemical events that lead to throm-
bosis of grafts is used as a guideline to describe possible counteracting prosthetic surface interventions in
each separate phase of the process.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Chapter 1. Deﬁning the Chain of Events
Introduction
The use of prosthetic grafts for repair of the arterial system is
one of the major advancements in modern vascular surgery.
Primarily consisting of polyester or expanded polytetraﬂuoro-
ethylene (ePTFE), these grafts have done well as a substitute for
occluded or stenosed arterial segments of large calibre, with
diameters equal to aortic, iliac or femoral arteries. Ever since bypass
surgery to the lower extremity was brought into practice, it is
known that the use of autologous vein grafts yields patency rates
exceeding those of prosthetic grafts.1
This is mainly because the exposure of the prosthetic graft
surface to blood plasma leads to the development of a ﬁbrinous
pseudointima and to a subsequent cascade of events in the pre-
existent ‘native’ intima.2 This layer tends to thicken over time and
causes narrowing of the luminal cross section, a process eventually
leading to thrombotic occlusion with graft failure. In locations
where native diameters are small, the effect of luminal narrowing is
unequivocal as ﬂow relates inversely to the fourth power of
diameter.3 As a consequence, every measure that stabilises the
formation of the ﬁbrin layer and that diminishes the proliferation of
the intimal layer is desirable.rtment of Surgery, Radboud
BNijmegen,TheNetherlands.
n der Vliet).
ciety for Vascular Surgery. PublisheUpon any intervention in the circulatory system, ﬂow patterns
are being inﬂuenced and changed.Whether this is by an autologous
graft, an in situ dilatation or a prosthetic graft, in all these cases the
phenomenon of vascular remodelling is recognised. Because the
wall of a prosthetic graft is stiff, the overall graft remodelling is
limited, and neointimal encroachment is the major determinant of
the luminal calibre.4 Since this review focusses on prosthetic graft
engineering, the process of intimal layer proliferation is emphas-
ised. Separating the cascade into speciﬁc key events has led to
a better understanding of this phenomenon. All these events may
serve as a target for biomedical intervention.
Intimal hyperplasia
Intimal hyperplasia is a chronic structural change occurring in
denuded arteries, arterialised veins and prosthetic bypass grafts. It
is determined by hyperproliferation and migration of vascular
smooth muscle cells (VSMCs) and is subdivided into hyperacute,
acute and chronic stages.5
The ﬁrst, hyperacute, stage is initiated by injury of an existing
genuine intimal lining or by platelet aggregation in thrombogenic,
non-autologous graft material. Proliferation of VSMCs is set in
through two mechanisms: (1) damaged endothelial cells produce
less inhibitors e prostacyclin, heparin sulphate, nitric oxide and
natriuretic peptides e to VSMC proliferation and 2) thrombocytes
themselves release heparinolytic enzymes. An increase occurs in
the release of growth-stimulating factors such as ﬁbroblast growth
factor 2 (FGF2) and platelet-derived growth factor A (PDGF-A).
In addition, angiotensin II, catecholamines and thrombin, alld by Elsevier Ltd. All rights reserved.
Figure 1. Hyperacute ﬁrst stage of intimal hyperplasia formation.
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of VSMCs (Fig. 1).
The second, acute, stage is characterised by the organisation of
the thrombus, endothelial cell ingrowth and, again, the release of
growth factors. In this stage, hours to weeks after injury, the
integrity of the extracellular matrix is affected, which stimulates
VSMCmigration from themedia to the intima. Both tissue-type and
urokinase-type plasminogen activator are involved in this reaction.
These agents activate matrix metalloproteases, further degrading
the extracellular matrix (Fig. 2).6
In the third and ﬁnal stage of intimal hyperplasia, new extra-
cellular matrix is synthesised, a process that may continue for
months after the initial lesion. In this stage, transforming growth
factor b (TGF-b) and PDGF are the main stimulating factors.7
Simultaneously, VSMC proliferation and migration, triggered in
the second stage, continue mediated by insulin-like growth factor
(IGF-1), TGF-b, thrombin and interleukin-1 (IL-1).8 Together, the
extracellular matrix synthesis and VSMC proliferation lead to
deﬁnitive intimal expansion (Fig. 3).
The behaviour of prosthetic grafts in relation to intimal hyperplasia
Because of the allogeneic properties of prosthetic graft mate-
rials, additional effects to those described above contribute to the
process of intimal hyperplasia. Several steps may be perceived: (1)
foreign-body reaction leads to an inﬂammatory reaction activating
macrophages which leads to newly excreted growth factors, (2)
uncovered graft material activates platelets which also producesFigure 2. Acute second stage of ingrowth factors, (3) VSMCs proliferate as a reaction to strain due to
non-physiological peri-anastomotic ﬂow patterns, (4) turbulence
itself causes injury to the endothelium of the adjacent native vessel
which releases growth factors and (5) platelets adhere to regions
with low shearing stress because of ﬂow separation which, again,
releases growth factors.9 Because the aforementioned events lead
to cell proliferation and extracellular matrix accumulation, they
ultimately lead to vessel narrowing and graft failure.
Controlling intimal hyperplasia in prosthetic grafts
By aiming at different key events in the intimal hyperplasia
cascade, the process may be down-regulated, possibly resulting in
less luminal narrowing. Hypothetical controllable events are sum-
marised in Table 1. Several molecular and pharmacologic therapies
have reached an applicable status to clinical practice and will be
addressed in the following section. A summary of clinically
accepted pharmacological agents and their points of action is
shown in Table 2.
Chapter 2. Systemic Factors Inﬂuencing Intimal Hyperplasia:
Stage 1
Platelet aggregation
Controlling thrombocyte activation and subsequent aggregation
has been a major issue since bypass surgery was ﬁrst undertaken.
Randomised clinical trials have proven beneﬁts of acetylsalicylictimal hyperplasia formation.
Figure 3. Chronic third stage of intimal hyperplasia formation.
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irreversibly inhibiting cyclooxygenase, so as to shift the production
of thromboxane A2ewhich serves as a platelet activity promotore
to the production of prostacyclin (PGI2), which inhibits platelet
activity by raising intracellular cyclic adenosine monophosphate
(cAMP). The beneﬁcial potential of the thienopyridine inhibitor
clopidogrel in infrainguinal bypass surgery has recently been
conﬁrmed.11
Endothelial surface inhibitors of platelet aggregation
In addition to anti-platelet drugs, platelet-inhibiting surface
coatings may serve as an interesting solution to platelet activation
by foreign-body contact.
Anti-platelet drug coating
The concept of linking anti-platelet agents to otherwise throm-
bogenic surfaces is very appealing. An in vitro study on immobilising
prostacyclin and prostaglandins to albuminated surfacesTable 1
Intimal hyperplasia pathobiology and possible targets for intervention.
Process Pathobiology Target
Stage 1 Intimal
hyperplasia
Platelet aggregation Cyclooxygenase
Glycoprotein IIb/
IIIa
Endothelial (surface) inhibitors of platelet
aggregation and SMC proliferation
Prostacyclin
Heparin sulphate
Nitric Oxide
Natriuretic
peptides
Enzymes released by platelets Heparinolytic
enzymes
Growth stimulating factors bFGF
PDGF
Other mediators Anginotensin II
Catecholamines
Thrombin
Stage 2 Intimal
hyperplasia
Extracellular matrix breakdown Urokinase
tPA
Matrix
metalloproteases
(MMP)
IGF-1
TGF-b
Thrombin
Interleukin-1
Stage 3 Intimal
hyperplasia
Extracellular matrix synthesis
Smooth muscle cell proliferation
TGF-b
PDGFdemonstrated that surfaces thusmodiﬁed caused negligible platelet
adherence.12 Also, impregnating prosthetic grafts with iloprost e
a prostacyclin analogue e conjugating dipyridamole to non-
autologous surfaces and a slow salicylic acid releasing polymer
coating were investigated. Data elicited from these experiments
demonstrated a dramatic decrease of in vitro thrombogenicity.13 A
major issue concerning all experiments with drug-eluting systems
appears to be the limitation of its action, because of the difﬁculties
in creating a stable and constant release of pharmacological agents.
Heparin coating
Intrinsic endothelial anti-thrombotic properties are mainly
dependent on heparan sulphate. Therefore, coating non-
endothelialised surfaces with the glycosaminoglycan heparin
might mimic the physiological situation. The key point is the
retention of its bioactivity, which is very much dependent on the
immobilising technique. Whereas heparin-bonded polyester grafts
did not show better patency rates at 5-year follow-up, a recently
published study comparing heparin-bonded ePTFE grafts to
conventional ePTFE grafts showed a signiﬁcant reduction in the
overall risk of primary graft failure.14,15
Nitric oxide coating
Nitric oxide has a variety of vasoprotective properties. It can
inhibit platelet adherence, decrease VSMC proliferation and
migration, promote endothelial regeneration and decrease leuco-
cyte chemotaxis.16 The development and clinical application of
polymeric biomaterials that provide a localised and sustained
production of nitric oxide may lead to reduction of thrombosis and
restenosis following vascular grafting of endovascular procedures.
The use of nitric oxide donor molecules that were covalently
incorporated into photopolymerised polyethylene glycol hydrogels
proved to be effective.17 Other techniques to incorporate nitric oxide
donors into thepolymer includeblending into thepolymerafter ion-
pairing and by simple dispersion within the polymer matrix.
Although each approach differs in terms of nitric oxide release rates,
mechanism and location, the release is maintained for 10e72 h. The
biomedical application of nitric oxide releasing or generating poly-
mers as a coating shows great promise as it may lead to a new
generation of medical devices with superior biocompatibility. The
impact that nitric oxide exerts on the inﬂammatory response to
vascular injury was recognised in diabetic rats, where a heightened
inﬂammatory response was associated with enhanced proliferative
activity and with greater neointima formation. It was indicated that
augmented inﬂammatory response and oxidative stress could be
reversed by increasing nitric oxide bioavailability.18
Table 2
Generic names of medication therapy, brand names, availability, point of action and feasibility of incorporating in synthetic surfaces.
Generic name Brand name FDA
approval
Point of action Graft incorporation
Rosuvastatin,
pravastatin
Crestor,
Selektin
Yes Inhibition of VSMC migration by impairing PDGF Unknown
Flavoperidol Alvocidib Yes Inhibition of VSMC growth by inhibition of bFGF Unknown
Rapamycin Sirolimus Yes Inhibition of VSMC migration by inhibition of IGF-1
Inhibition of endothelial cell proliferation by inhibition of bFGF
Yes, collagen matrix
Paclitaxel Taxol Yes Inhibition of VSMC and endothelial cell proliferation and migration
by preventing DNA-synthesis initiated by growth factors
Yes, collagen matrix
Heparin e Yes Inhibition of VSMC growth and proliferation by indirect thrombin
inhibition
Yes, collagen matrix
Nitric oxide e Yes Inhibits vascular smooth muscle growth, platelet aggregation, and
leukocyte adhesion to the endothelium
Yes, incorporation into photopolymerized
polyethylene glycol hydrogels
Dexamethasone e Yes Multiple points of action; mainly anti-inﬂammatory effects Yes, suspension in lactic acid matrix or
impregnation in polymer matrix
Acetylsalicylic acid Aspirin Yes Inhibition of platelet activity by raising cAMP activity Yes, polymer matrix
Ticlopidine Ticlid Yes Decreasing platelet activity and aggregation, no effect on IH No
Clopidogrel Plavix Yes Decreasing platelet activity and aggregation, no effect on IH No
Iloprost Ilomedine Yes Raises intracellular cAMP and decreases platelet aggregation Unknown
Ramipril Tritace Yes Inhibits conversion to angiotensin II No
Troglitazone Resulin Yes Inhibits PDGF, IGF-1 and bFGF No
Argatroban e Yes Direct thrombin inhibition No
Lepirudine Reﬂudan Yes Direct thrombin inhibition No
Tranilast e Yes Inhibition of proliferation and migration of VSMC, mechanism not fully
revealed
No
Abciximab Reopro Yes Decreasing platelet activity and aggregation, probably also effect on
SMC proliferation and migration
Yes
Celiprolol Dilanorm Yes Increasing nitric oxide production, reducing intimal hyperplasia No
D.M. Scharn et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 66e72 69Natriuretic peptide coating
C-type natriuretic peptide has strong vasorelaxant properties. It
appears to be an important factor regulating vascular tone. In
humans, a strong expression of natriuretic peptide receptors in
neointimal VSMCs has been conﬁrmed by analysis of post-mortem
atherectomy specimens.19 The therapeutic relevance of natriuretic
peptide has yet to be determined, but interventions that selectively
modulate its production or activity may be of therapeutic beneﬁt.
Enzymes released by platelets and growth-stimulating factors
Platelets are intensely involved in the ﬁrst stage of intimal
hyperplasia. Enzymes that are released from platelets at the site of
vascular injury comprise growth-stimulating factors. Basic ﬁbro-
blast growth factor (FGF2) has been shown to play an instrumental
role in the cascade of events leading to restenosis. Release of hep-
aranase and platelet factor-4 (PF4) by activated platelets liberates
FGF2 from the extracellular matrix of VSMCs. FGF2 has been
determined to be an important smooth muscle cell mitogen.
Treatment with intravenous FGF2-neutralising antibodies signiﬁ-
cantly decreased post-injury VSMC proliferation.20
Another growth factor playing an important role in the early
events following vascular injury is PDGF. PDGF is a mitogen and
chemoattractant for VSMCs in vitro but induces only minimal
increases in medial VSMC proliferation following vascular injury in
the rat carotid artery.21 Its main action is centred on the enhance-
ment of intimal thickening by promoting the migration of VSMCs
from the media to the intima rather than stimulating their prolif-
eration. Since its action is dependent on luminal factors, the use of
barrier agents, precluding blood and foreign-body contact, may
limit the cascade leading to intimal hyperplasia.
Other mediators
The coagulation protein thrombin (activated Factor II) is a serine
protease that converts soluble ﬁbrinogen into insoluble strands of
ﬁbrin, as well as catalysing many other coagulation-relatedreactions. It functions as a key trigger of thrombosis and contrib-
utes to structural changes in the arterial wall that promote nar-
rowing and clotting.22 As the mechanisms bywhich thrombin leads
to intimal thickening are well understood, the idea of counteracting
its actions by medical intervention is tempting, since many agents
exist that inhibit the effects of thrombin. Direct thrombin inhibitors
are clinically used as anticoagulants. Other thrombin inhibitors
recently investigated are argatroban, melagatran, dabigatran,
bivalirudin and the recombinant hirudins including lepirudin and
desirudin.23
Interfering in the renineangiotensin cascade also affects the
process of intimal hyperplasia. Blocking of angiotensin II type 1
receptors attenuates neointimal formation. This is due to the
interaction between the renineangiotensin system and the homing
process of VSMCs upon arterial wall injury. While the exact
mechanism for this interaction is not yet fully understood, the
effects of angiotensin-converting enzyme inhibiting pharmaceuti-
cals such as ramipril and elanapril on intimal hyperplasia have been
tested in an animal model.24 Application of these drugs, either by
direct administration or indirectly by the use of drug-eluting stent
grafts, seems attractive.
The process of VSMC proliferation, hypertrophy andmigration is
also stimulated by catecholamines, through stimulation of a1-
adrenoreceptors.25 It is suggested that catecholamines may
contribute to excessive growth of vascular wall cells in vascular
diseases and injury after surgical procedures. Moreover, Hattori and
co-workers demonstrated that chronic administration of the b-
adrenergic blocker celiprolol inhibits vein graft intimal hyperplasia
through suppression of proliferative activity in the neointima.26
Platelet glycoprotein IIb/IIIa inhibitors such as abciximab have
shown to be effective in reducing thrombotic events in patients
undergoing coronary interventions and with acute coronary
syndromes.27 They affect platelet function by occupying the
ﬁbrinogen-binding site on the platelet surface, thus preventing
cross-linking of platelets by ﬁbrinogen during thrombus formation
induced by plaque disruption and rupture. In this manner, abcix-
imab is active in inhibiting platelet aggregation and VSMC
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expression in vessel lumens and neointimal VSMCs after angio-
plasty. Clinical therapeutic beneﬁt has been tested in coronary
stenting practice, showing a potential therapeutic beneﬁt in pre-
venting in-stent stenoses using abciximab-coated stent material.28
Chapter 3. Factors Inﬂuencing Intimal Hyperplasia: Stage 2
Extracellular matrix breakdown
The extracellular matrix includes the interstitial matrix, the
inner elastic lamina and the basement membrane. The interstitial
matrix consists of ﬁbrous proteins and glycosaminoglycans,
produced by resident VSMCs. It can vary in its composition by
adapting to different stimuli. In healthy tissue, the matrix proteins
are stable and have a slow turnover rate. In the early response
after vascular wall injury, the matrix is affected by serine
proteinases. Later, rebuilding of the extracellular matrix takes
place, which is merged with VSMC proliferation and migration,
leading to vascular wall thickening. Matrix degradation is facili-
tated by matrix metalloproteases (MMPs). Activation of MMP
production induced by injury is initiated by the serine proteinase
tissue-type plasminogen activator (tPA) and urokinase-type
plasminogen activator (urokinase) synthesised by vascular endo-
thelial and VSMCs. Drugs or agents that control production of
these mediators may play a role in attenuating this phase of
intimal hyperplasia.
Lijnen and co-workers studied the effect of high-dose urokinase
in injured murine arteries.29 They found that reduced activity of
some MMPs correlated with protection from neointimal formation
and from breakdown of medial lamellar matrix. Although mecha-
nisms in human vascular disease appear to be more complex,
interfering in MMP and plasminogen activating agent production
seems attractive. Long-term effects of treatment with thrombolytic
agents in atherosclerotic cardiovascular diseases remain to be
deﬁned.
Chapter 4. Factors Inﬂuencing Intimal Hyperplasia: Stage 3
Extracellular matrix synthesis
The plasminogen activator system not only participates in
extracellular matrix breakdown, but also plays a key role in
modulating haemostasis, thrombosis and several other biological
processes.30 Overexpression of urokinase promotes neointima
formation, which is probably due to active remodelling of extra-
cellular matrix caused by excess plasmin. A role for urokinase in
VSMC migration and neointima formation is conﬁrmed, but not for
tPA.31 Upon vascular wall injury, monocytes are recruited to the site
of injury, resulting in modulation of VSMC growth and migration.
This interaction plays a central role in the development of vascular
intimal thickening. Urokinase expressed by monocytes serves as
a potent chemotactic factor for VSMCs and therefore might account
for the acceleration of vascular remodelling.32
As ﬁbroblast growth factors promote medial proliferation of
VSMCs, migration of these cells to the intima is mainly promoted by
endogenous or exogenous PDGF.33 Insulin-like growth factor-1
(IGF-1), TGF-b, thrombin and IL-1 all take part in this process.
IGF-1 is a mitogen that exerts its effects through speciﬁc receptors
located on the cell membrane and promotes the multiplication of
VSMCs in culture. Blocking IGF-1-mediated phosphorylation of the
IGF-1 receptor in VSMCs inhibits their replication, and subse-
quently attenuates intimal hyperplasia after balloon injury of rat
carotid arteries.34 PDGF and TGF-b are potent VSMC mitogens
in vitro and induce VSMC chemotaxis. Their receptors belong toa family of growth factor receptors, each sharing the common
feature of activation of tyrosine kinase upon binding of growth
factors. Somatostatin e a growth-inhibitory peptide found
throughout the body e inhibits the stimulatory effects of selected
growth factors by activating speciﬁc protein tyrosine phosphatases.
Clinical use of these ﬁndings has been suggested by the use of
somatostatin analogues in reducing restenosis after coronary artery
interventions.35
Other conventional, systemically delivered drugs have been
shown to inhibit VSMC proliferation and migration. Of these, tro-
glitazone appeared to reduce neointimal formation in patients
with noninsulin-dependent diabetes mellitus receiving coronary
stent implantation, whereas tranilast reduced in-stent restenosis
in the porcine coronary model but appears to show no clinical
beneﬁt.36
Cytokines are also important agents involved in this phase of
intimal neoformation as intimal hyperplasia occurs by way of
inﬂammation-dependent mechanisms.37 IL-1 is an inﬂammatory
cytokine that stimulates expression of adhesion molecules and
induces synthesis of other proinﬂammatory cytokines. Also, IL-1
acts as a chemoattractant and mitogen for VSMCs and is overex-
pressed at sites of active proliferation andmigration of these cells at
the site of injury. It has been demonstrated that IL-1 receptor gene-
deﬁcient mice tend to develop less neointima and recent studies
revealed a crucial role for an IL-1 receptor antagonist in the
reduction of inﬂammation in both intima and adventitia and
inhibition of neointimal formation.38 Although it exerts effects in
many ways, dexamethasone strongly prevents neointimal growth
by its anti-inﬂammatory effects, inhibiting leucocyte adhesion and
aggregation. However, systemic side effects preclude its clinical
use.39
Since vascular narrowing has been referred to as a central
feature of chronic rejection in transplanted organs, the inﬂuence of
modern immunosuppressive agents on the process of intimal
expansion has been studied.40 While VSMCs in mature, normal
blood vessels exhibit a differentiated, quiescent, contractile
morphology, injury induces a phenotypic modulation towards
a proliferative, dedifferentiated, migratory and synthetic pheno-
type with up-regulated extracellular matrix synthesis, which
contributes to intimal hyperplasia. The mammalian target of
rapamycin (mTOR) appears to play a key role in VSMC proliferation
and migration. The antiproliferative effects of rapamycin on VSMCs
are attributed to an inhibition of mTOR, resulting in blocked cell-
cycle progression at the G1/S transition.41 Rapamycin also inhibi-
ted rat and human VSMC migration in response to PDGF, although
the mechanisms by which this takes place are less clear.42
Rapamycin-coated stents or grafts may lead to the prevention of
(re-)stenosis. It is compelling to use rapamycin in graft coatings, as
it may promote the maintenance of functional, quiescent VSMCs at
the site of injury or anastomosis.
Along with the recently evolving potential of genetic engi-
neering, the idea of modifying the tendency of VSMCs to proliferate
by genetic interference is very appealing. By manipulating the
phenotype expressed on vascular endothelial cells, the emerging
cascade of intimal hyperplasia could possibly be inﬂuenced. One
way to achieve this is by true genetic modiﬁcation introducing
a gene of interest by transfection, as has been studied in cell-seeded
synthetic grafts.43 Another compelling method to change VSMC
behaviour genetically aimed at a speciﬁc molecular strategy, by
intra-operative treatment of harvested vein grafts with a decoy
DNA molecule in order to eliminate transcripting factor activity.44
Although this large prospective study presented disappointing
primary results, it showed that intra-operative genetic intervention
to modulate the vascular injury response can be executed safely
and with high surgical and scientiﬁc quality.
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Modelling the graft’s surface
Creating a graft surface less hostile to blood components by
resembling autologous tissue should also be addressed here. Dar-
dik’s achievement in investigating and producing grafts lined with
human endothelial cells prepared the way for the concept of artiﬁ-
cially lining synthetic grafts with human endothelial tissue by cell
seeding.45 Synthetic vascular grafts do not spontaneously endo-
thelialise and thus usually require some form of anticoagulation to
maintain patency. Hence, endothelialisation of prosthetic implants
became an attractive concept. A number of different methods of
obtaining an endothelial lining of prosthetic material have since
beendeveloped. These include facilitated cellmigration and seeding
by using either venous or microvascular endothelial cells. Although
excellent in vitro resultswere obtainedwith prosthetic graft seeding
with endothelial progenitor cells, none of these studies reported
favourable effects on the clinically relevant end points, such as
intimal hyperplasia or graft patency.46 In spite of this, manipulating
the endothelium might well provide the next major advancement
for therapeutic and preventive measures for cardiovascular disease.
Separating blood components from a potential thrombogenic
surface using artiﬁcially created layers may serve as another way to
create an interface less liable to the initiation of thrombogenic
reactions upon implantation. It has been demonstrated that 20-
micron-thick hydrogel barriers adhering ﬁrmly to the arterial wall
block thrombus deposition after deliberate injury to carotid
arteries.47 If these nonthrombogenic hydrogel barriers were to be
applied to the luminal surface of a prosthetic vascular graft, this
would result in the reduction of blood contact and, as such, might
reduce extracellular matrix proliferation and migration after
prosthetic vascular graft bypass surgery.
Modelling ﬂow patterns
Haemodynamic factors contribute to changes in the blood vessel
wall. Altered haemodynamic forces are crucial for the remodelling
of vein grafts and both low- and high-ﬂow conditions may serve as
a trigger for developing intimal hyperplasia.48 Atherosclerotic
plaques, intimal hyperplasia after angioplasty and vein graft
thickening are all increased in areas of low shear. Graft stenosis due
to intimal hyperplasia occurs predominantly in anastomotic areas,
where disturbed ﬂow patterns and low shear stress lead to vessel
wall thickening. Both in vitro and in vivo studies have shown that
a large number of growth factors are regulated by shear stress, of
which PDGF, FGF2 and TGF-b have been pointed out as the most
important mediators.49
To prevent disadvantageous ﬂow patterns at the anastomosis,
the application of venous cuffs or patches evolved to ensure a more
gradual transition from graft to native vessel. As an alternative,
precuffed bypass grafts have been designed. In peripheral bypass
graft surgery, a randomised clinical trial showed similar patency
results for precuffed grafts and PTFE grafts with vein cuff.50
Another, more recently published study addressed the use of
a vein collar for the distal anastomosis of below-knee femo-
ropopliteal and femorodistal grafts but failed to show signiﬁcant
differences in primary and secondary patency or limb salvage, with
or without a vein collar, respectively.51
Chapter 6. Conclusion
As scientiﬁc boundaries are shifting and surgical techniques are
reﬁned, new treatment modalities come within reach. Under-
standing the principles of graft failure and elucidating thebiological events responsible are of paramount importance.
Bioscience and molecular chemical engineering have converged,
aiming at the creation of a durable, nonthrombogenic, biocom-
patible, inﬁnitely available and, thus, practically ideal synthetic
bypass graft material.
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